

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	29.2	68.4	(41.8-105.7)	Male	18	18.8	95.5	(56.6-151.0)
Female	8	10.7	74.8	(32.2-147.4)	Female	12	14.7	81.6	(42.1-142.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.4	nc	(nc-nc)	Male	7	6.0	116.5	(46.7-240.0)
Female	6	4.7	126.3	(46.1-275.0)	Female	1	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	15	16.6	90.4	(50.5-149.1)
Female	129	119.4	108.1	(90.2-128.4)	Female	11	14.7	74.6	(37.2-133.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	9	14.4	62.4	(28.5-118.4)
<u>Colon / Rectum</u>					Female	6	6.5	93.0	(34.0-202.4)
Male	36	31.2	115.6	(80.9-160.0)	<u>Ovary</u>				
Female	31	31.0	100.1	(68.0-142.0)	Female	15	10.2	146.5	(81.9-241.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.5	nc	(nc-nc)	Male	13	10.9	118.8	(63.2-203.1)
Female	3	2.1	nc	(nc-nc)	Female	11	11.2	98.2	(48.9-175.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.0	nc	(nc-nc)	Male	114	91.1	125.1	(103.2-150.3)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.9	115.7	(49.8-228.0)
Male	17	17.2	98.8	(57.5-158.2)	Female	4	4.3	nc	(nc-nc)
Female	8	9.5	84.5	(36.4-166.5)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.6	166.3	(60.7-362.0)
Male	4	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
<u>Leukemia</u>					Female	24	21.2	113.2	(72.5-168.4)
Male	9	11.6	77.4	(35.3-147.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.6	93.1	(40.1-183.4)	Female	21	26.8	78.4	(48.5-119.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	10.6	84.6	(38.6-160.6)	Male	389	376.4	103.4	(93.3-114.2)
Female	3	3.5	nc	(nc-nc)	Female	386	398.4	96.9	(87.5-107.0)
<u>Lung and Bronchus</u>									
Male	53	50.8	104.4	(78.2-136.5)					
Female	50	55.4	90.2	(67.0-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	57.7	97.0	(73.3-126.0)	Male	19	37.0	51.4	(30.9-80.3)
Female	23	21.4	107.5	(68.2-161.4)	Female	16	29.5	54.3	(31.0-88.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	11.6	137.7	(78.7-223.7)	Male	9	11.6	77.6	(35.4-147.3)
Female	13	10.1	128.2	(68.2-219.2)	Female	6	9.8	61.3	(22.4-133.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.0	nc	(nc-nc)	Male	28	33.0	84.8	(56.3-122.5)
Female	251	223.0	112.6	(99.1-127.4)	Female	30	29.0	103.5	(69.8-147.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	7.4	134.8	(64.6-248.0)	Male	16	26.3	60.8	(34.7-98.8)
<u>Colon / Rectum</u>					Female	9	12.7	70.8	(32.3-134.5)
Male	67	59.2	113.1	(87.6-143.6)	<u>Ovary</u>				
Female	65	60.7	107.1	(82.7-136.5)	Female	21	19.9	105.4	(65.2-161.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	14.2	63.3	(28.9-120.2)	Male	29	21.0	138.1	(92.5-198.3)
Female	6	4.1	145.2	(53.0-316.1)	Female	23	22.5	102.4	(64.9-153.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.5	108.6	(39.6-236.3)	Male	141	166.9	84.5	(71.1-99.6)
Female	5	4.8	104.3	(33.6-243.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	13.4	127.0	(74.0-203.4)
Male	36	32.2	111.7	(78.2-154.6)	Female	13	8.6	151.4	(80.5-258.9)
Female	23	18.4	125.2	(79.3-187.8)	<u>Testis</u>				
<u>Larynx</u>					Male	12	11.0	109.4	(56.5-191.1)
Male	6	8.2	73.0	(26.7-158.9)	<u>Thyroid</u>				
Female	3	2.5	nc	(nc-nc)	Male	23	15.5	148.6	(94.2-223.1)
<u>Leukemia</u>					Female	44	43.8	100.4	(72.9-134.8)
Male	20	23.9	83.6	(51.1-129.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	17.9	89.4	(51.1-145.2)	Female	44	51.0	86.3	(62.7-115.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	19.7	111.9	(70.1-169.4)	Male	690	729.3	94.6	(87.7-101.9)
Female	4	7.1	nc	(nc-nc)	Female	774	778.4	99.4	(92.6-106.7)
<u>Lung and Bronchus</u>									
Male	106	99.9	106.1	(86.8-128.3)					
Female	102	109.1	93.5	(76.2-113.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.2	98.2	(48.9-175.7)	Male	4	7.2	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	5	5.4	93.2	(30.0-217.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.4	109.0	(43.7-224.7)
Female	39	45.0	86.6	(61.6-118.3)	Female	7	5.3	133.3	(53.4-274.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.4	nc	(nc-nc)
Male	14	11.9	118.1	(64.5-198.2)	<u>Ovary</u>				
Female	11	10.7	103.1	(51.4-184.5)	Female	4	3.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.9	nc	(nc-nc)	Male	8	4.2	189.4	(81.5-373.2)
Female	1	0.8	nc	(nc-nc)	Female	7	3.9	177.7	(71.2-366.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	24	36.7	65.5	(41.9-97.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.7	nc	(nc-nc)
Male	3	6.7	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	6	3.6	169.0	(61.7-367.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.1	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.0	nc	(nc-nc)	Female	12	10.5	114.4	(59.1-199.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.1	120.6	(38.9-281.5)	Male	134	146.8	91.3	(76.5-108.1)
Female	2	1.3	nc	(nc-nc)	Female	141	147.1	95.8	(80.7-113.0)
<u>Lung and Bronchus</u>									
Male	23	19.8	116.1	(73.6-174.2)					
Female	20	20.8	96.2	(58.7-148.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	29.4	132.6	(94.3-181.3)	Male	14	18.2	76.8	(41.9-128.8)
Female	21	9.6	218.4	(135.2-333.9)	Female	13	13.2	98.6	(52.4-168.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.1	196.8	(94.2-361.9)	Male	8	5.9	135.7	(58.4-267.4)
Female	1	4.3	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	16.1	112.1	(66.4-177.1)
Female	94	109.3	86.0	(69.5-105.3)	Female	8	13.2	60.5	(26.0-119.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	15	13.0	115.6	(64.7-190.7)
<u>Colon / Rectum</u>					Female	9	5.9	152.6	(69.6-289.7)
Male	33	29.6	111.4	(76.7-156.5)	<u>Ovary</u>				
Female	36	26.8	134.1	(93.9-185.7)	Female	7	9.4	74.7	(29.9-153.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.1	126.0	(57.5-239.1)	Male	17	10.6	159.8	(93.0-255.9)
Female	1	1.9	nc	(nc-nc)	Female	17	9.9	172.2	(100.3-275.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	88	83.3	105.7	(84.8-130.2)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.7	nc	(nc-nc)
Male	13	15.9	81.6	(43.4-139.5)	Female	3	3.8	nc	(nc-nc)
Female	15	8.8	170.9	(95.6-281.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.1	160.7	(51.8-375.1)
Male	3	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	7	6.6	106.6	(42.7-219.6)
<u>Leukemia</u>					Female	20	19.3	103.6	(63.3-160.0)
Male	15	11.3	133.0	(74.4-219.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	7.7	195.9	(109.6-323.1)	Female	24	25.4	94.5	(60.5-140.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	9.8	152.7	(85.4-251.9)	Male	418	359.4	116.3	(105.4-128.0)
Female	5	3.3	152.3	(49.1-355.5)	Female	408	362.4	112.6	(101.9-124.1)
<u>Lung and Bronchus</u>									
Male	71	51.7	137.4	(107.3-173.3)					
Female	74	51.8	143.0	(112.2-179.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	98.2	(31.6-229.1)	Male	2	3.4	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	15	21.8	68.7	(38.4-113.4)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	8	5.7	140.9	(60.7-277.6)	<u>Ovary</u>				
Female	6	5.5	110.0	(40.2-239.5)	Female	0	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.4	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	17.9	72.5	(38.6-123.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.3	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	7	4.7	150.0	(60.1-309.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	Male	64	70.4	90.9	(70.0-116.1)
Female	0	0.6	nc	(nc-nc)	Female	53	71.6	74.1	(55.5-96.9)
<u>Lung and Bronchus</u>									
Male	8	9.2	87.1	(37.5-171.7)					
Female	9	9.7	92.5	(42.2-175.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	4.1	120.6	(38.9-281.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	17.1	76.1	(40.5-130.1)
Female	0	0.1	nc	(nc-nc)	Female	14	14.4	97.0	(53.0-162.8)
<u>Lung and Bronchus</u>									
Male	2	2.5	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	12.7	39.5	(12.7-92.2)
Female	1	0.1	nc	(nc-nc)	Female	9	9.9	91.3	(41.7-173.4)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	29.4	98.5	(66.0-141.5)	Male	12	19.7	61.0	(31.5-106.6)
Female	8	12.7	62.9	(27.1-123.9)	Female	21	18.2	115.6	(71.6-176.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.3	95.9	(35.0-208.8)	Male	8	6.2	129.4	(55.7-255.0)
Female	7	5.9	118.7	(47.6-244.7)	Female	5	6.0	83.9	(27.0-195.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	13	17.6	74.0	(39.3-126.5)
Female	160	140.5	113.8	(96.9-132.9)	Female	16	17.6	90.9	(51.9-147.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.7	192.8	(88.0-366.0)	Male	12	14.8	81.3	(41.9-142.0)
<u>Colon / Rectum</u>					Female	13	7.8	166.8	(88.7-285.3)
Male	42	32.2	130.4	(94.0-176.3)	<u>Ovary</u>				
Female	33	35.5	92.8	(63.9-130.4)	Female	17	12.3	138.6	(80.7-221.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.6	92.7	(37.1-191.0)	Male	13	11.0	117.7	(62.6-201.4)
Female	1	2.5	nc	(nc-nc)	Female	17	13.3	128.1	(74.6-205.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.8	nc	(nc-nc)	Male	72	90.7	79.4	(62.1-100.0)
Female	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	7.1	141.7	(67.8-260.5)
Male	14	18.0	78.0	(42.6-130.8)	Female	8	5.0	158.9	(68.4-313.2)
Female	3	11.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.9	84.8	(27.3-198.0)
Male	7	4.4	157.7	(63.2-324.9)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	9	8.8	102.3	(46.7-194.2)
<u>Leukemia</u>					Female	35	27.5	127.2	(88.6-177.0)
Male	17	12.5	135.7	(79.0-217.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	10.3	125.8	(66.9-215.1)	Female	27	32.9	82.1	(54.1-119.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.8	55.5	(20.3-120.9)	Male	373	389.1	95.9	(86.4-106.1)
Female	5	4.2	118.4	(38.2-276.3)	Female	499	478.1	104.4	(95.4-113.9)
<u>Lung and Bronchus</u>									
Male	52	51.5	100.9	(75.4-132.4)					
Female	60	67.7	88.7	(67.7-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.9	95.1	(55.4-152.3)	Male	23	11.3	204.1	(129.4-306.3)
Female	6	6.4	93.4	(34.1-203.2)	Female	12	8.6	139.6	(72.1-243.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.9	80.9	(34.9-159.5)
Female	77	72.5	106.2	(83.8-132.7)	Female	12	8.7	137.3	(70.9-239.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	5	8.2	60.8	(19.6-141.8)
<u>Colon / Rectum</u>					Female	4	3.9	nc	(nc-nc)
Male	13	18.5	70.3	(37.4-120.2)	<u>Ovary</u>				
Female	11	18.0	61.2	(30.5-109.4)	Female	4	6.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.5	nc	(nc-nc)	Male	5	6.6	76.2	(24.5-177.7)
Female	1	1.2	nc	(nc-nc)	Female	8	6.6	121.5	(52.3-239.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	65	51.9	125.3	(96.7-159.7)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.2	nc	(nc-nc)
Male	7	10.1	69.6	(27.9-143.3)	Female	0	2.5	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.7	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	4.2	141.7	(51.8-308.5)
<u>Leukemia</u>					Female	12	12.2	98.5	(50.8-172.0)
Male	6	6.9	86.9	(31.7-189.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.9	nc	(nc-nc)	Female	13	16.6	78.4	(41.7-134.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.1	nc	(nc-nc)	Male	203	221.9	91.5	(79.3-105.0)
Female	0	2.1	nc	(nc-nc)	Female	210	239.0	87.9	(76.4-100.6)
<u>Lung and Bronchus</u>									
Male	16	31.4	51.0	(29.1-82.8)					
Female	19	34.6	54.9	(33.0-85.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	21.3	117.4	(76.0-173.3)	Male	12	13.0	92.6	(47.8-161.8)
Female	5	7.2	69.0	(22.2-161.0)	Female	8	9.8	81.6	(35.2-160.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	3.3	180.9	(66.1-393.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	13	11.4	113.8	(60.5-194.6)
Female	81	76.3	106.2	(84.3-132.0)	Female	11	9.7	113.0	(56.3-202.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	16	9.2	174.3	(99.5-283.0)
<u>Colon / Rectum</u>					Female	5	4.3	117.5	(37.9-274.1)
Male	20	21.5	93.0	(56.8-143.6)	<u>Ovary</u>				
Female	19	20.9	90.8	(54.6-141.8)	Female	14	6.7	208.6	(113.9-350.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.1	136.7	(54.8-281.7)	Male	8	7.6	105.2	(45.3-207.3)
Female	3	1.4	nc	(nc-nc)	Female	10	7.6	131.2	(62.8-241.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	58	59.1	98.2	(74.6-127.0)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.8	nc	(nc-nc)
Male	11	11.2	97.9	(48.8-175.1)	Female	2	2.9	nc	(nc-nc)
Female	10	6.2	160.5	(76.8-295.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	6	2.9	205.3	(75.0-447.0)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	5	4.7	107.0	(34.5-249.8)
<u>Leukemia</u>					Female	16	14.3	111.7	(63.8-181.5)
Male	7	8.1	86.3	(34.6-177.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.9	101.5	(37.1-221.0)	Female	22	16.8	130.6	(81.8-197.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	6.9	145.0	(69.4-266.6)	Male	292	256.2	114.0	(101.3-127.8)
Female	5	2.4	212.0	(68.3-494.9)	Female	321	262.6	122.3	(109.2-136.4)
<u>Lung and Bronchus</u>									
Male	49	36.3	134.9	(99.8-178.3)					
Female	59	36.9	159.8	(121.7-206.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	30.2	62.9	(37.8-98.2)	Male	35	19.0	183.8	(128.0-255.6)
Female	8	9.9	80.6	(34.7-158.8)	Female	26	14.3	181.8	(118.7-266.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	5.5	nc	(nc-nc)	Male	6	6.2	96.8	(35.3-210.7)
Female	7	5.1	136.1	(54.5-280.5)	Female	7	4.7	150.5	(60.3-310.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	16.9	88.6	(49.6-146.2)
Female	147	117.4	125.2	(105.8-147.2)	Female	7	14.0	50.0	(20.0-103.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	10	14.0	71.7	(34.3-131.8)
<u>Colon / Rectum</u>					Female	5	6.2	80.8	(26.0-188.5)
Male	23	31.3	73.4	(46.5-110.2)	<u>Ovary</u>				
Female	24	29.2	82.3	(52.7-122.4)	Female	11	9.9	110.6	(55.1-198.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	7.5	nc	(nc-nc)	Male	8	11.1	72.1	(31.0-142.1)
Female	1	1.9	nc	(nc-nc)	Female	9	10.3	87.3	(39.8-165.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	113	88.4	127.9	(105.4-153.7)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	7.0	99.5	(39.8-204.9)
Male	15	17.2	87.4	(48.9-144.2)	Female	2	4.1	nc	(nc-nc)
Female	5	9.2	54.5	(17.6-127.1)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.2	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	7.4	95.0	(38.1-195.7)
<u>Leukemia</u>					Female	21	22.4	93.8	(58.0-143.3)
Male	12	12.0	99.9	(51.5-174.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.4	106.5	(48.6-202.3)	Female	26	25.4	102.5	(66.9-150.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.3	58.2	(21.3-126.7)	Male	322	377.5	85.3	(76.2-95.2)
Female	1	3.3	nc	(nc-nc)	Female	387	385.6	100.4	(90.6-110.9)
<u>Lung and Bronchus</u>									
Male	18	52.5	34.3	(20.3-54.2)					
Female	35	52.0	67.3	(46.9-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.2	nc	(nc-nc)	Male	5	3.6	138.6	(44.7-323.5)
Female	2	2.8	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.1	223.8	(89.7-461.1)
Female	22	25.8	85.4	(53.5-129.3)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	7	5.8	121.1	(48.5-249.6)	<u>Ovary</u>				
Female	4	7.1	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	2.9	173.6	(55.9-405.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	19.0	78.8	(44.1-130.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.2	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.0	nc	(nc-nc)	Male	63	74.5	84.5	(64.9-108.1)
Female	1	0.9	nc	(nc-nc)	Female	71	90.5	78.5	(61.3-99.0)
<u>Lung and Bronchus</u>									
Male	3	11.3	nc	(nc-nc)					
Female	10	14.8	67.7	(32.4-124.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	14	16.8	83.5	(45.6-140.1)
Female	0	0.1	nc	(nc-nc)	Female	11	15.1	73.0	(36.4-130.6)
<u>Lung and Bronchus</u>									
Male	4	2.3	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.8	103.9	(38.0-226.3)	Male	6	3.4	176.0	(64.3-383.1)
Female	1	2.0	nc	(nc-nc)	Female	7	2.6	272.2	(109.0-560.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.1	162.4	(52.3-379.0)
Female	27	20.7	130.5	(86.0-189.9)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<u>Ovary</u>				
Female	8	5.7	139.2	(59.9-274.2)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	14.0	142.9	(87.3-220.7)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.5	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	6	4.6	131.3	(48.0-285.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	66	65.8	100.3	(77.6-127.6)
Female	0	0.7	nc	(nc-nc)	Female	83	71.2	116.6	(92.9-144.6)
<u>Lung and Bronchus</u>									
Male	3	9.8	nc	(nc-nc)					
Female	11	10.1	109.2	(54.4-195.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	9.0	187.9	(109.4-300.8)	Male	8	5.9	134.6	(58.0-265.3)
Female	5	3.1	159.6	(51.4-372.4)	Female	3	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
Female	23	29.8	77.1	(48.9-115.7)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.4	113.4	(36.6-264.7)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	5	9.5	52.8	(17.0-123.3)	<u>Ovary</u>				
Female	7	8.8	79.9	(32.0-164.7)	Female	5	2.7	187.2	(60.3-436.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	28	28.2	99.3	(66.0-143.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	9	5.3	168.3	(76.8-319.5)	Female	1	1.2	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	9	4.7	191.8	(87.5-364.2)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.4	nc	(nc-nc)	Female	5	6.8	73.4	(23.7-171.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	136	118.7	114.6	(96.1-135.5)
Female	0	1.0	nc	(nc-nc)	Female	108	105.6	102.2	(83.9-123.4)
<u>Lung and Bronchus</u>									
Male	25	15.9	157.1	(101.6-231.9)					
Female	13	15.8	82.4	(43.9-141.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.6	104.0	(49.8-191.2)	Male	10	5.9	170.8	(81.8-314.2)
Female	3	2.7	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.2	172.5	(78.7-327.5)
Female	38	31.5	120.6	(85.4-165.6)	Female	8	3.8	211.2	(90.9-416.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	7	4.2	167.3	(67.0-344.8)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	8	9.7	82.3	(35.4-162.2)	<u>Ovary</u>				
Female	17	7.9	215.2	(125.3-344.5)	Female	2	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	21	27.3	76.9	(47.6-117.6)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.2	nc	(nc-nc)
Male	5	5.1	97.9	(31.5-228.4)	Female	0	1.1	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	5.7	192.7	(96.1-344.9)
Male	0	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.2	nc	(nc-nc)	Female	5	7.2	69.2	(22.3-161.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	117	116.6	100.3	(83.0-120.3)
Female	0	0.9	nc	(nc-nc)	Female	124	104.1	119.1	(99.1-142.0)
<u>Lung and Bronchus</u>									
Male	18	16.4	110.1	(65.2-174.0)					
Female	16	14.1	113.1	(64.6-183.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.3	nc	(nc-nc)	Male	5	3.3	152.7	(49.2-356.4)
Female	0	2.1	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	16	19.2	83.2	(47.5-135.2)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.1	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	5.8	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	16.2	68.1	(33.9-121.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	5	2.9	169.6	(54.6-395.7)	Female	1	0.8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.0	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.6	nc	(nc-nc)	Female	6	4.4	134.9	(49.3-293.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.9	nc	(nc-nc)	Male	50	66.1	75.7	(56.2-99.8)
Female	0	0.7	nc	(nc-nc)	Female	61	69.0	88.4	(67.6-113.6)
<u>Lung and Bronchus</u>									
Male	9	9.2	97.4	(44.5-185.0)					
Female	13	10.3	126.1	(67.1-215.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.3	149.8	(64.5-295.1)	Male	3	3.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	22	20.2	108.7	(68.1-164.6)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<u>Ovary</u>				
Female	2	4.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	23	17.4	132.4	(83.9-198.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	7	3.2	219.2	(87.8-451.6)	Female	0	0.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	66	69.7	94.7	(73.2-120.5)
Female	0	0.6	nc	(nc-nc)	Female	50	64.4	77.7	(57.6-102.4)
<u>Lung and Bronchus</u>									
Male	2	9.3	nc	(nc-nc)					
Female	4	8.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	29.4	118.9	(82.8-165.4)	Male	14	19.0	73.9	(40.4-124.0)
Female	11	11.5	95.5	(47.6-170.8)	Female	9	15.9	56.5	(25.8-107.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.8	120.5	(48.3-248.3)	Male	2	6.1	nc	(nc-nc)
Female	9	5.2	172.9	(78.9-328.2)	Female	4	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	17.0	106.1	(62.9-167.8)
Female	117	127.4	91.8	(75.9-110.0)	Female	16	15.7	102.1	(58.3-165.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.1	193.1	(83.2-380.6)	Male	18	14.3	125.5	(74.3-198.3)
<u>Colon / Rectum</u>					Female	7	7.0	100.4	(40.2-207.0)
Male	52	30.7	169.1	(126.3-221.8)	<u>Ovary</u>				
Female	37	32.9	112.3	(79.1-154.8)	Female	7	11.1	63.2	(25.3-130.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	7.6	171.7	(91.3-293.6)	Male	10	11.0	90.8	(43.5-167.1)
Female	1	2.2	nc	(nc-nc)	Female	10	12.0	83.2	(39.9-153.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.3	nc	(nc-nc)	Male	79	91.9	85.9	(68.0-107.1)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.9	72.2	(23.3-168.4)
Male	15	17.3	86.9	(48.6-143.4)	Female	5	4.6	108.4	(34.9-253.1)
Female	13	10.2	126.9	(67.5-217.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.1	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	10	7.7	130.5	(62.5-240.0)
<u>Leukemia</u>					Female	18	23.5	76.5	(45.3-120.9)
Male	12	12.2	98.6	(50.9-172.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	9.4	139.0	(73.9-237.7)	Female	27	28.8	93.7	(61.7-136.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	10.8	111.0	(57.3-193.9)	Male	389	381.3	102.0	(92.1-112.7)
Female	4	3.9	nc	(nc-nc)	Female	439	429.1	102.3	(93.0-112.3)
<u>Lung and Bronchus</u>									
Male	54	51.6	104.6	(78.6-136.5)					
Female	82	60.1	136.4	(108.5-169.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.4	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.1	84.5	(30.9-184.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	27	27.1	99.5	(65.6-144.8)
Female	0	0.2	nc	(nc-nc)	Female	15	23.0	65.1	(36.4-107.4)
<u>Lung and Bronchus</u>									
Male	7	3.9	179.9	(72.1-370.7)					
Female	0	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	3.1	257.5	(110.9-507.3)	Male	6	1.9	311.3	(113.7-677.6)
Female	1	1.6	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	20	18.4	108.8	(66.4-168.1)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	17	11.5	147.6	(85.9-236.3)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	3	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.8	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	63	41.6	151.4	(116.3-193.7)
Female	0	0.6	nc	(nc-nc)	Female	49	60.9	80.5	(59.5-106.4)
<u>Lung and Bronchus</u>									
Male	2	5.9	nc	(nc-nc)					
Female	4	8.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	18.2	76.8	(41.9-128.8)	Male	14	12.2	114.9	(62.8-192.8)
Female	7	6.5	107.0	(42.8-220.4)	Female	9	9.7	92.8	(42.3-176.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	6	3.2	188.6	(68.9-410.4)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	8	10.8	73.9	(31.8-145.7)
Female	87	77.7	112.0	(89.7-138.1)	Female	5	9.2	54.1	(17.4-126.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	9	9.2	98.0	(44.7-186.0)
<u>Colon / Rectum</u>					Female	3	4.1	nc	(nc-nc)
Male	16	20.1	79.6	(45.5-129.3)	<u>Ovary</u>				
Female	14	19.5	72.0	(39.3-120.7)	Female	5	6.5	76.6	(24.7-178.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.7	nc	(nc-nc)	Male	8	6.9	116.8	(50.3-230.1)
Female	3	1.3	nc	(nc-nc)	Female	9	6.8	131.5	(60.0-249.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	59	55.0	107.3	(81.7-138.4)
Female	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	114.0	(36.8-266.1)
Male	5	11.2	44.8	(14.4-104.6)	Female	3	2.8	nc	(nc-nc)
Female	3	6.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.1	158.9	(51.2-370.7)
Male	1	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	7	5.4	130.6	(52.3-269.2)
<u>Leukemia</u>					Female	14	15.4	91.1	(49.7-152.8)
Male	10	7.6	131.6	(63.0-242.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.6	179.6	(86.0-330.3)	Female	22	16.8	130.8	(82.0-198.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.6	91.1	(33.3-198.4)	Male	222	238.7	93.0	(81.2-106.1)
Female	2	2.2	nc	(nc-nc)	Female	261	255.4	102.2	(90.2-115.4)
<u>Lung and Bronchus</u>									
Male	18	31.9	56.4	(33.4-89.1)					
Female	32	34.0	94.1	(64.3-132.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	43.8	100.5	(73.0-134.9)	Male	20	27.7	72.2	(44.1-111.5)
Female	12	15.8	76.1	(39.3-132.9)	Female	19	21.5	88.2	(53.1-137.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.4	nc	(nc-nc)	Male	10	9.0	111.3	(53.3-204.8)
Female	4	7.3	nc	(nc-nc)	Female	4	7.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	22	24.7	89.0	(55.8-134.7)
Female	196	174.8	112.1	(97.0-129.0)	Female	28	21.6	129.7	(86.2-187.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.5	145.8	(62.8-287.4)	Male	24	20.5	116.9	(74.9-174.0)
<u>Colon / Rectum</u>					Female	8	9.6	83.4	(35.9-164.3)
Male	67	45.1	148.7	(115.2-188.8)	<u>Ovary</u>				
Female	50	44.6	112.1	(83.2-147.8)	Female	19	15.2	125.2	(75.4-195.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	11.1	171.4	(103.1-267.7)	Male	13	16.1	80.6	(42.9-137.9)
Female	4	3.1	nc	(nc-nc)	Female	10	16.4	60.9	(29.2-112.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.2	155.4	(50.1-362.5)	Male	125	132.4	94.4	(78.6-112.4)
Female	0	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	10.2	117.6	(60.7-205.4)
Male	26	24.9	104.3	(68.1-152.9)	Female	11	6.3	174.7	(87.1-312.7)
Female	7	14.1	49.8	(19.9-102.6)	<u>Testis</u>				
<u>Larynx</u>					Male	11	5.6	195.4	(97.4-349.7)
Male	5	6.4	78.0	(25.1-182.0)	<u>Thyroid</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	10.8	46.1	(14.9-107.6)
<u>Leukemia</u>					Female	23	31.3	73.4	(46.5-110.1)
Male	18	17.8	101.2	(60.0-160.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	12.8	70.4	(32.1-133.6)	Female	34	40.2	84.5	(58.5-118.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	15.4	64.8	(31.0-119.1)	Male	571	555.8	102.7	(94.5-111.5)
Female	4	5.3	nc	(nc-nc)	Female	565	587.7	96.1	(88.4-104.4)
<u>Lung and Bronchus</u>									
Male	86	76.7	112.1	(89.7-138.5)					
Female	81	83.1	97.5	(77.5-121.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	22.3	67.2	(37.6-110.9)	Male	14	15.5	90.6	(49.5-152.0)
Female	3	7.1	nc	(nc-nc)	Female	16	11.6	137.7	(78.7-223.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.8	168.2	(72.4-331.4)	Male	8	5.0	161.6	(69.6-318.4)
Female	4	3.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	13	13.6	95.4	(50.7-163.1)
Female	114	97.9	116.4	(96.0-139.8)	Female	8	10.6	75.4	(32.5-148.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.5	nc	(nc-nc)	Male	6	12.4	48.4	(17.7-105.4)
<u>Colon / Rectum</u>					Female	4	4.9	nc	(nc-nc)
Male	21	25.5	82.5	(51.0-126.1)	<u>Ovary</u>				
Female	37	21.5	171.9	(121.0-236.9)	Female	5	8.0	62.1	(20.0-145.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.1	nc	(nc-nc)	Male	8	8.7	91.9	(39.5-181.0)
Female	2	1.4	nc	(nc-nc)	Female	5	7.2	69.0	(22.2-161.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	92	74.7	123.2	(99.3-151.1)
Female	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.5	126.4	(50.6-260.4)
Male	11	14.9	74.0	(36.9-132.4)	Female	1	3.0	nc	(nc-nc)
Female	1	7.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	5	3.6	138.7	(44.7-323.8)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	10	7.0	142.9	(68.4-262.8)
<u>Leukemia</u>					Female	17	19.8	85.9	(50.0-137.5)
Male	10	9.5	105.3	(50.4-193.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.2	113.8	(45.6-234.5)	Female	32	21.5	149.0	(101.9-210.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.7	57.4	(18.5-133.9)	Male	295	307.2	96.0	(85.4-107.6)
Female	1	2.5	nc	(nc-nc)	Female	317	304.9	104.0	(92.8-116.1)
<u>Lung and Bronchus</u>									
Male	26	40.5	64.2	(42.0-94.1)					
Female	31	39.0	79.5	(54.0-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	6	1.6	379.3	(138.5-825.7)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	9	8.5	106.0	(48.4-201.2)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	8.1	98.5	(42.4-194.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	25	32.0	78.0	(50.5-115.2)
Female	0	0.2	nc	(nc-nc)	Female	18	26.9	66.8	(39.6-105.6)
<u>Lung and Bronchus</u>									
Male	4	4.4	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	85.4	(34.2-175.9)	Male	6	5.5	109.5	(40.0-238.4)
Female	3	2.2	nc	(nc-nc)	Female	7	3.7	189.0	(75.7-389.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.9	123.3	(45.0-268.4)
Female	42	31.3	134.0	(96.6-181.1)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.6	nc	(nc-nc)
Male	4	9.1	nc	(nc-nc)	<u>Ovary</u>				
Female	7	6.5	108.0	(43.3-222.6)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	22	28.0	78.5	(49.2-118.9)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.0	nc	(nc-nc)
Male	8	5.2	154.0	(66.3-303.5)	Female	0	0.9	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	9	6.3	143.5	(65.5-272.5)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	9	7.4	122.1	(55.7-231.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.2	nc	(nc-nc)	Male	88	111.2	79.1	(63.5-97.5)
Female	0	0.8	nc	(nc-nc)	Female	112	97.0	115.5	(95.1-138.9)
<u>Lung and Bronchus</u>									
Male	8	14.3	56.0	(24.1-110.3)					
Female	14	12.3	113.8	(62.2-190.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.4	110.3	(64.2-176.6)	Male	14	9.6	145.4	(79.4-244.0)
Female	1	5.1	nc	(nc-nc)	Female	7	6.9	101.0	(40.4-208.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	8.4	142.2	(73.4-248.3)
Female	56	57.2	97.9	(73.9-127.1)	Female	3	6.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	7	7.1	98.8	(39.6-203.6)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	11	15.6	70.4	(35.1-125.9)	<u>Ovary</u>				
Female	11	14.6	75.3	(37.5-134.7)	Female	2	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.9	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	13	5.3	245.6	(130.7-420.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	45	46.1	97.6	(71.2-130.7)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.6	nc	(nc-nc)
Male	6	8.7	69.3	(25.3-150.8)	Female	0	2.1	nc	(nc-nc)
Female	0	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.5	141.7	(45.7-330.7)
<u>Leukemia</u>					Female	8	10.0	80.3	(34.6-158.2)
Male	5	6.0	83.3	(26.8-194.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.1	120.6	(38.9-281.4)	Female	9	12.8	70.1	(32.0-133.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.3	94.6	(30.5-220.8)	Male	176	192.1	91.6	(78.6-106.2)
Female	1	1.7	nc	(nc-nc)	Female	145	190.1	76.3	(64.4-89.8)
<u>Lung and Bronchus</u>									
Male	16	27.2	58.8	(33.6-95.5)					
Female	11	26.6	41.4	(20.6-74.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	22.8	118.3	(77.9-172.1)	Male	13	13.8	94.0	(50.0-160.8)
Female	4	7.6	nc	(nc-nc)	Female	5	10.1	49.6	(16.0-115.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	6	4.6	131.7	(48.1-286.7)
Female	2	3.2	nc	(nc-nc)	Female	5	3.6	139.8	(45.1-326.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	12.3	122.3	(68.4-201.8)
Female	78	84.2	92.7	(73.3-115.7)	Female	16	10.3	155.0	(88.5-251.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	7	9.9	71.0	(28.4-146.2)
<u>Colon / Rectum</u>					Female	4	4.6	nc	(nc-nc)
Male	23	22.5	102.0	(64.7-153.1)	<u>Ovary</u>				
Female	21	21.2	98.9	(61.2-151.2)	Female	6	7.1	84.4	(30.8-183.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.6	142.2	(61.2-280.3)	Male	12	8.2	145.8	(75.3-254.8)
Female	0	1.5	nc	(nc-nc)	Female	11	8.0	136.8	(68.2-244.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	95	67.6	140.6	(113.7-171.8)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.2	96.0	(30.9-224.0)
Male	12	12.3	97.6	(50.4-170.6)	Female	2	3.0	nc	(nc-nc)
Female	6	6.7	89.7	(32.8-195.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.2	226.8	(73.1-529.3)
Male	3	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	6	5.0	120.2	(43.9-261.7)
<u>Leukemia</u>					Female	17	14.0	121.2	(70.6-194.1)
Male	7	8.6	81.2	(32.5-167.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.8	85.9	(27.7-200.4)	Female	14	19.7	71.1	(38.8-119.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.5	nc	(nc-nc)	Male	312	279.0	111.8	(99.8-125.0)
Female	1	2.5	nc	(nc-nc)	Female	259	280.4	92.4	(81.5-104.3)
<u>Lung and Bronchus</u>									
Male	37	39.8	93.1	(65.5-128.3)					
Female	37	40.3	91.8	(64.6-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	22.5	79.9	(47.3-126.3)	Male	26	13.6	191.6	(125.1-280.7)
Female	6	7.8	77.2	(28.2-168.0)	Female	15	9.9	151.7	(84.8-250.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	11	4.4	250.9	(125.1-448.9)
Female	4	3.2	nc	(nc-nc)	Female	6	3.5	170.7	(62.3-371.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	8	12.0	66.5	(28.6-131.0)
Female	103	78.8	130.8	(106.7-158.6)	Female	5	10.2	49.0	(15.8-114.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	7	9.5	73.4	(29.4-151.3)
<u>Colon / Rectum</u>					Female	6	4.4	136.5	(49.8-297.1)
Male	18	22.8	79.0	(46.8-124.8)	<u>Ovary</u>				
Female	15	22.7	65.9	(36.9-108.8)	Female	7	6.8	102.3	(41.0-210.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	5.3	nc	(nc-nc)	Male	13	8.1	161.2	(85.7-275.6)
Female	1	1.5	nc	(nc-nc)	Female	2	8.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	62	60.0	103.3	(79.2-132.4)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	5.1	nc	(nc-nc)
Male	12	11.6	103.6	(53.5-181.0)	Female	2	3.2	nc	(nc-nc)
Female	6	6.4	94.0	(34.3-204.5)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.8	329.8	(120.4-717.9)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	20	13.4	149.6	(91.3-231.0)
Male	10	8.4	119.6	(57.2-219.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.2	162.3	(77.7-298.4)	Female	18	16.8	106.8	(63.3-168.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.3	96.4	(38.6-198.6)	Male	259	265.3	97.6	(86.1-110.2)
Female	4	2.5	nc	(nc-nc)	Female	283	271.7	104.2	(92.4-117.0)
<u>Lung and Bronchus</u>									
Male	25	37.5	66.6	(43.1-98.3)					
Female	31	38.4	80.8	(54.9-114.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	59.9	113.5	(88.1-143.9)	Male	43	38.7	111.0	(80.3-149.5)
Female	37	25.1	147.3	(103.7-203.0)	Female	53	34.3	154.7	(115.9-202.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.4	78.8	(36.0-149.6)	Male	12	12.4	97.0	(50.1-169.5)
Female	10	11.0	91.1	(43.6-167.5)	Female	6	11.8	51.0	(18.6-110.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	2.1	nc	(nc-nc)	Male	40	34.2	116.9	(83.5-159.2)
Female	290	279.3	103.8	(92.2-116.5)	Female	29	34.4	84.3	(56.4-121.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	8.8	nc	(nc-nc)	Male	27	28.4	94.9	(62.5-138.1)
<u>Colon / Rectum</u>					Female	23	15.2	150.9	(95.6-226.4)
Male	70	62.5	112.1	(87.3-141.6)	<u>Ovary</u>				
Female	68	70.3	96.7	(75.1-122.6)	Female	22	23.9	91.9	(57.6-139.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	15.1	125.7	(75.7-196.4)	Male	18	22.2	81.2	(48.1-128.3)
Female	8	5.0	161.3	(69.4-317.8)	Female	22	26.1	84.1	(52.7-127.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	4.5	133.9	(48.9-291.5)	Male	162	178.7	90.6	(77.2-105.7)
Female	2	4.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	14.1	99.5	(54.4-167.0)
Male	36	34.7	103.7	(72.6-143.5)	Female	7	10.0	70.3	(28.2-144.9)
Female	28	22.4	125.2	(83.2-180.9)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.5	117.6	(56.3-216.4)
Male	17	8.8	192.4	(112.0-308.0)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	14	15.6	89.6	(48.9-150.4)
<u>Leukemia</u>					Female	44	49.4	89.0	(64.7-119.5)
Male	18	24.2	74.4	(44.1-117.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	19.8	70.7	(38.6-118.6)	Female	71	64.9	109.5	(85.5-138.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	21.2	94.5	(57.7-145.9)	Male	813	764.0	106.4	(99.2-114.0)
Female	9	8.4	107.0	(48.8-203.1)	Female	959	934.4	102.6	(96.2-109.3)
<u>Lung and Bronchus</u>									
Male	134	106.1	126.3	(105.9-149.6)					
Female	154	133.1	115.7	(98.2-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	7.4	67.4	(21.7-157.3)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.5	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.2	113.5	(45.5-233.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	25	22.7	110.4	(71.4-162.9)
Female	0	0.2	nc	(nc-nc)	Female	14	24.3	57.7	(31.5-96.8)
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	3	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	13.3	157.4	(97.4-240.7)	Male	11	9.2	119.6	(59.6-214.0)
Female	11	4.8	227.9	(113.6-407.8)	Female	14	7.5	186.1	(101.7-312.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	8.1	nc	(nc-nc)
Female	54	60.9	88.6	(66.6-115.6)	Female	4	7.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.1	nc	(nc-nc)	Male	9	7.2	124.4	(56.8-236.2)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	17	14.9	114.2	(66.5-182.8)	<u>Ovary</u>				
Female	15	14.2	105.9	(59.2-174.6)	Female	2	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	139.1	(44.8-324.5)	Male	3	5.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	6	5.0	120.7	(44.1-262.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	43	44.6	96.4	(69.7-129.8)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.3	nc	(nc-nc)
Male	20	8.7	228.7	(139.6-353.2)	Female	1	2.0	nc	(nc-nc)
Female	3	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.3	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	5	4.2	120.3	(38.8-280.7)
<u>Leukemia</u>					Female	13	12.2	106.3	(56.6-181.8)
Male	7	5.7	122.4	(49.0-252.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.2	nc	(nc-nc)	Female	6	13.9	43.2	(15.8-93.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.2	nc	(nc-nc)	Male	195	183.3	106.4	(92.0-122.4)
Female	0	1.7	nc	(nc-nc)	Female	203	196.9	103.1	(89.4-118.3)
<u>Lung and Bronchus</u>									
Male	26	24.3	106.8	(69.8-156.5)					
Female	43	26.0	165.2	(119.5-222.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	22.3	76.2	(44.4-122.1)	Male	17	13.5	125.9	(73.3-201.7)
Female	11	7.0	157.1	(78.3-281.1)	Female	9	9.2	98.4	(44.9-186.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	6	2.9	205.2	(74.9-446.5)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	8	11.9	67.3	(29.0-132.6)
Female	81	74.3	109.0	(86.6-135.5)	Female	10	9.3	107.9	(51.6-198.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	11	9.9	111.6	(55.6-199.7)
<u>Colon / Rectum</u>					Female	3	4.1	nc	(nc-nc)
Male	18	22.4	80.4	(47.6-127.0)	<u>Ovary</u>				
Female	12	20.5	58.7	(30.3-102.5)	Female	10	6.4	157.0	(75.2-288.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	5.4	nc	(nc-nc)	Male	2	8.1	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	9	7.5	120.2	(54.9-228.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	45	65.8	68.4	(49.9-91.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.1	nc	(nc-nc)
Male	9	11.9	75.3	(34.4-143.0)	Female	3	2.9	nc	(nc-nc)
Female	4	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	4.7	106.2	(34.2-247.9)
<u>Leukemia</u>					Female	10	12.6	79.3	(38.0-145.9)
Male	4	8.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.6	107.8	(39.4-234.7)	Female	10	16.4	61.1	(29.3-112.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.4	80.8	(29.5-175.9)	Male	204	271.5	75.1	(65.2-86.2)
Female	2	2.2	nc	(nc-nc)	Female	238	251.6	94.6	(82.9-107.4)
<u>Lung and Bronchus</u>									
Male	26	38.4	67.8	(44.3-99.3)					
Female	27	35.2	76.7	(50.5-111.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.4	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	14.4	132.2	(79.5-206.4)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.6	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	11.3	44.3	(14.3-103.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	5	3.5	144.1	(46.4-336.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	28	44.3	63.2	(42.0-91.3)
Female	0	0.4	nc	(nc-nc)	Female	45	47.4	94.9	(69.2-127.0)
<u>Lung and Bronchus</u>									
Male	4	6.3	nc	(nc-nc)					
Female	3	6.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.9	91.3	(41.7-173.3)	Male	7	5.6	125.1	(50.1-257.7)
Female	3	3.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	139.8	(56.0-288.1)
Female	21	33.7	62.4	(38.6-95.4)	Female	3	4.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	6	9.3	64.8	(23.7-141.1)	<u>Ovary</u>				
Female	6	10.5	56.9	(20.8-123.9)	Female	2	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	25.1	83.8	(51.8-128.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.1	nc	(nc-nc)
Male	6	4.5	131.9	(48.2-287.2)	Female	0	1.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	0	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.9	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.0	nc	(nc-nc)	Male	83	111.0	74.8	(59.6-92.7)
Female	3	1.2	nc	(nc-nc)	Female	83	123.8	67.1	(53.4-83.1)
<u>Lung and Bronchus</u>									
Male	5	16.2	30.8	(9.9-72.0)					
Female	16	18.8	85.1	(48.6-138.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	23.9	100.5	(64.4-149.5)	Male	12	15.4	77.8	(40.2-136.0)
Female	6	8.6	70.0	(25.6-152.3)	Female	12	12.6	95.4	(49.2-166.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.6	107.9	(34.8-251.8)	Male	4	4.9	nc	(nc-nc)
Female	5	4.1	122.9	(39.6-286.7)	Female	4	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	13.8	72.5	(34.7-133.4)
Female	121	101.9	118.7	(98.5-141.9)	Female	17	12.1	140.1	(81.6-224.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	12	11.6	103.5	(53.4-180.8)
<u>Colon / Rectum</u>					Female	4	5.4	nc	(nc-nc)
Male	23	25.6	89.7	(56.8-134.6)	<u>Ovary</u>				
Female	29	25.3	114.6	(76.8-164.7)	Female	6	8.7	69.1	(25.2-150.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	6.0	nc	(nc-nc)	Male	8	8.9	89.9	(38.7-177.1)
Female	0	1.7	nc	(nc-nc)	Female	7	9.0	77.9	(31.2-160.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.8	nc	(nc-nc)	Male	48	72.8	66.0	(48.6-87.4)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.6	nc	(nc-nc)
Male	20	14.1	141.9	(86.7-219.2)	Female	5	3.5	140.9	(45.4-328.8)
Female	5	8.0	62.8	(20.2-146.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.4	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	8	6.4	124.4	(53.6-245.1)
<u>Leukemia</u>					Female	14	19.4	72.3	(39.5-121.4)
Male	14	9.8	143.3	(78.3-240.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.1	70.0	(22.5-163.3)	Female	20	23.0	86.9	(53.1-134.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.5	82.5	(33.0-169.9)	Male	270	307.1	87.9	(77.7-99.1)
Female	2	2.9	nc	(nc-nc)	Female	340	334.5	101.6	(91.1-113.0)
<u>Lung and Bronchus</u>									
Male	43	41.1	104.6	(75.7-140.9)					
Female	45	44.8	100.5	(73.3-134.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.9	75.6	(34.5-143.5)	Male	1	7.7	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	73.9	(23.8-172.3)
Female	35	47.3	74.0	(51.5-102.9)	Female	1	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.5	nc	(nc-nc)	Male	11	5.7	194.6	(97.0-348.2)
<u>Colon / Rectum</u>					Female	0	2.5	nc	(nc-nc)
Male	10	12.6	79.4	(38.0-146.1)	<u>Ovary</u>				
Female	16	11.1	144.4	(82.5-234.6)	Female	4	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.0	167.3	(53.9-390.5)	Male	9	4.4	204.5	(93.3-388.2)
Female	1	0.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	19	35.1	54.1	(32.5-84.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	8	6.9	116.6	(50.2-229.7)	Female	2	1.5	nc	(nc-nc)
Female	8	3.7	217.2	(93.5-428.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.7	69.0	(25.2-150.1)
Male	4	4.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.1	nc	(nc-nc)	Female	7	10.8	64.7	(25.9-133.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.2	nc	(nc-nc)	Male	123	151.2	81.4	(67.6-97.1)
Female	1	1.3	nc	(nc-nc)	Female	129	152.2	84.7	(70.7-100.7)
<u>Lung and Bronchus</u>									
Male	16	20.8	76.8	(43.8-124.7)					
Female	21	20.9	100.5	(62.2-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	24.8	80.7	(49.3-124.6)	Male	16	16.0	100.0	(57.1-162.3)
Female	8	9.3	86.0	(37.0-169.4)	Female	13	13.0	100.1	(53.3-171.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	129.8	(47.4-282.5)	Male	6	5.1	117.6	(42.9-256.0)
Female	4	4.2	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.1	106.2	(59.4-175.2)
Female	116	106.2	109.3	(90.3-131.1)	Female	14	12.8	109.7	(60.0-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	7	11.6	60.3	(24.1-124.2)
<u>Colon / Rectum</u>					Female	7	5.7	123.4	(49.4-254.2)
Male	26	26.1	99.7	(65.1-146.1)	<u>Ovary</u>				
Female	25	27.1	92.4	(59.8-136.4)	Female	9	8.9	101.1	(46.1-192.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.1	nc	(nc-nc)	Male	8	9.2	87.2	(37.5-171.8)
Female	0	1.8	nc	(nc-nc)	Female	9	9.8	91.4	(41.7-173.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	73	71.3	102.4	(80.2-128.7)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.8	nc	(nc-nc)
Male	9	14.4	62.7	(28.6-119.0)	Female	2	3.8	nc	(nc-nc)
Female	16	8.4	191.4	(109.3-310.8)	<u>Testis</u>				
<u>Larynx</u>					Male	0	3.1	nc	(nc-nc)
Male	0	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	6.4	108.6	(43.5-223.8)
<u>Leukemia</u>					Female	20	19.5	102.4	(62.5-158.2)
Male	16	10.0	160.5	(91.7-260.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.6	105.3	(45.3-207.5)	Female	26	23.2	111.8	(73.0-163.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.5	70.9	(25.9-154.4)	Male	277	311.8	88.8	(78.7-99.9)
Female	2	3.0	nc	(nc-nc)	Female	356	351.6	101.2	(91.0-112.3)
<u>Lung and Bronchus</u>									
Male	25	43.4	57.5	(37.2-84.9)					
Female	38	48.5	78.3	(55.4-107.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	4.5	111.6	(36.0-260.3)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	6	1.4	414.9	(151.5-903.1)	<u>Ovary</u>				
Female	2	0.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	4.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	18.0	83.3	(46.6-137.4)
Female	0	0.1	nc	(nc-nc)	Female	19	13.7	138.3	(83.2-216.0)
<u>Lung and Bronchus</u>									
Male	1	2.4	nc	(nc-nc)					
Female	3	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	22.4	84.9	(51.1-132.6)	Male	25	14.2	176.0	(113.9-259.9)
Female	10	7.6	130.9	(62.7-240.8)	Female	24	10.8	223.2	(143.0-332.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.1	nc	(nc-nc)	Male	7	4.6	151.0	(60.5-311.2)
Female	3	3.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	9	12.5	71.9	(32.8-136.4)
Female	84	88.1	95.4	(76.1-118.1)	Female	6	10.6	56.5	(20.6-123.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	6	10.5	57.1	(20.8-124.2)
<u>Colon / Rectum</u>					Female	5	4.7	106.2	(34.2-247.9)
Male	29	22.7	127.9	(85.6-183.7)	<u>Ovary</u>				
Female	26	21.6	120.3	(78.5-176.2)	Female	5	7.6	66.2	(21.3-154.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	5.7	157.3	(71.8-298.7)	Male	16	8.3	193.1	(110.3-313.7)
Female	1	1.5	nc	(nc-nc)	Female	5	7.8	63.8	(20.6-149.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	66	69.0	95.7	(74.0-121.7)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.2	134.4	(53.8-276.9)
Male	20	12.8	156.6	(95.6-241.9)	Female	4	3.0	nc	(nc-nc)
Female	8	7.0	114.0	(49.1-224.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	9	5.4	167.3	(76.4-317.6)
<u>Leukemia</u>					Female	9	16.2	55.5	(25.3-105.4)
Male	3	8.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	6.1	146.5	(66.9-278.2)	Female	23	20.1	114.3	(72.4-171.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.0	87.4	(35.0-180.2)	Male	316	284.6	111.0	(99.1-124.0)
Female	2	2.6	nc	(nc-nc)	Female	307	291.3	105.4	(93.9-117.9)
<u>Lung and Bronchus</u>									
Male	54	40.1	134.8	(101.3-175.9)					
Female	56	41.1	136.1	(102.8-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	43.7	121.4	(90.9-158.8)	Male	31	27.7	111.9	(76.0-158.8)
Female	23	15.6	147.1	(93.2-220.7)	Female	14	21.4	65.5	(35.8-110.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.2	nc	(nc-nc)	Male	10	8.7	114.4	(54.8-210.5)
Female	9	6.9	130.5	(59.5-247.7)	Female	6	7.2	83.4	(30.5-181.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	34	24.5	138.6	(96.0-193.7)
Female	208	166.2	125.2	(108.7-143.4)	Female	29	21.2	136.9	(91.7-196.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	5.4	202.8	(101.1-362.9)	Male	15	19.9	75.3	(42.1-124.3)
<u>Colon / Rectum</u>					Female	6	9.2	65.0	(23.7-141.4)
Male	56	45.0	124.3	(93.9-161.4)	<u>Ovary</u>				
Female	53	44.8	118.3	(88.6-154.7)	Female	13	14.6	89.0	(47.3-152.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.7	103.1	(51.4-184.5)	Male	10	15.9	63.0	(30.2-115.8)
Female	0	3.0	nc	(nc-nc)	Female	15	16.3	91.8	(51.3-151.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.4	nc	(nc-nc)	Male	108	124.6	86.6	(71.1-104.6)
Female	2	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	10.1	108.9	(54.3-194.9)
Male	27	24.3	111.2	(73.3-161.8)	Female	7	6.3	110.9	(44.4-228.5)
Female	13	13.5	96.2	(51.2-164.5)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.7	104.1	(41.7-214.4)
Male	4	6.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	1.9	nc	(nc-nc)	Male	13	11.1	117.0	(62.3-200.2)
<u>Leukemia</u>					Female	38	31.0	122.7	(86.8-168.4)
Male	14	17.6	79.6	(43.5-133.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.7	94.3	(48.6-164.7)	Female	29	37.4	77.4	(51.9-111.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	14.9	121.1	(71.7-191.4)	Male	588	544.3	108.0	(99.5-117.1)
Female	2	5.2	nc	(nc-nc)	Female	634	569.7	111.3	(102.8-120.3)
<u>Lung and Bronchus</u>									
Male	101	75.2	134.4	(109.4-163.3)					
Female	88	80.0	109.9	(88.2-135.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	167	163.7	102.0	(87.1-118.7)	Male	73	106.2	68.7	(53.9-86.4)
Female	60	62.8	95.5	(72.9-123.0)	Female	68	88.8	76.6	(59.5-97.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	31	33.6	92.2	(62.6-130.8)	Male	29	33.5	86.6	(58.0-124.3)
Female	22	30.2	72.9	(45.7-110.4)	Female	25	29.0	86.1	(55.7-127.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	5.7	nc	(nc-nc)	Male	96	95.2	100.9	(81.7-123.2)
Female	634	692.0	91.6	(84.6-99.0)	Female	65	86.2	75.4	(58.2-96.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	31	23.2	133.4	(90.6-189.4)	Male	69	78.3	88.2	(68.6-111.6)
<u>Colon / Rectum</u>					Female	47	38.1	123.2	(90.5-163.9)
Male	164	174.3	94.1	(80.2-109.6)	<u>Ovary</u>				
Female	159	181.8	87.4	(74.4-102.1)	Female	52	60.7	85.7	(64.0-112.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	56	40.9	137.1	(103.5-178.0)	Male	66	60.4	109.3	(84.5-139.0)
Female	16	12.1	132.0	(75.4-214.4)	Female	70	65.8	106.3	(82.9-134.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	13	14.6	88.9	(47.3-152.1)	Male	424	477.3	88.8	(80.6-97.7)
Female	18	13.1	137.2	(81.2-216.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	39	38.5	101.4	(72.1-138.6)
Male	97	94.7	102.5	(83.1-125.0)	Female	20	25.5	78.4	(47.9-121.1)
Female	66	55.9	118.1	(91.4-150.3)	<u>Testis</u>				
<u>Larynx</u>					Male	22	28.3	77.7	(48.7-117.7)
Male	22	23.6	93.3	(58.5-141.3)	<u>Thyroid</u>				
Female	12	7.7	156.2	(80.6-272.8)	Male	43	45.0	95.5	(69.1-128.7)
<u>Leukemia</u>					Female	136	135.2	100.6	(84.4-118.9)
Male	70	69.3	101.0	(78.7-127.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	57	52.9	107.7	(81.5-139.5)	Female	176	154.3	114.0	(97.8-132.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	75	57.6	130.2	(102.4-163.2)	Male	2052	2092.8	98.0	(93.9-102.4)
Female	27	20.8	129.6	(85.4-188.5)	Female	2313	2353.6	98.3	(94.3-102.4)
<u>Lung and Bronchus</u>									
Male	329	280.3	117.4	(105.0-130.8)					
Female	347	325.0	106.8	(95.8-118.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	8	6.6	121.3	(52.2-238.9)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	6.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	6	1.6	371.8	(135.8-809.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.7	nc	(nc-nc)	Male	23	24.4	94.1	(59.6-141.2)
Female	0	0.2	nc	(nc-nc)	Female	23	21.1	109.1	(69.1-163.6)
<u>Lung and Bronchus</u>									
Male	7	3.4	208.2	(83.4-429.1)					
Female	0	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.3	116.2	(60.0-202.9)	Male	9	7.2	124.4	(56.8-236.1)
Female	3	4.5	nc	(nc-nc)	Female	11	6.4	173.2	(86.3-309.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.3	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	6.4	203.8	(108.4-348.6)
Female	62	51.5	120.4	(92.3-154.4)	Female	6	6.3	95.8	(35.0-208.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.7	nc	(nc-nc)
Male	18	12.1	148.6	(88.1-234.9)	<u>Ovary</u>				
Female	13	13.3	98.1	(52.2-167.8)	Female	9	4.4	204.4	(93.3-388.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.8	nc	(nc-nc)	Male	7	4.1	172.2	(69.0-354.9)
Female	0	0.8	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	56	34.7	161.5	(122.0-209.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	8	6.9	115.6	(49.8-227.7)	Female	2	1.9	nc	(nc-nc)
Female	5	4.0	123.6	(39.8-288.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	8	3.2	246.8	(106.3-486.3)
<u>Leukemia</u>					Female	9	9.5	94.7	(43.2-179.8)
Male	4	4.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.7	nc	(nc-nc)	Female	6	11.2	53.4	(19.5-116.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	184	143.5	128.2	(110.3-148.1)
Female	2	1.5	nc	(nc-nc)	Female	170	169.8	100.1	(85.6-116.3)
<u>Lung and Bronchus</u>									
Male	17	18.6	91.6	(53.3-146.6)					
Female	15	22.9	65.5	(36.6-108.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	47.0	106.5	(79.0-140.4)	Male	52	26.1	199.0	(148.6-261.0)
Female	22	17.4	126.1	(79.0-190.9)	Female	43	19.2	224.5	(162.4-302.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.3	111.1	(44.5-228.8)	Male	9	8.5	105.7	(48.2-200.7)
Female	6	6.1	98.3	(35.9-213.9)	Female	6	7.6	78.7	(28.7-171.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	21	23.1	90.9	(56.3-139.0)
Female	181	154.6	117.1	(100.6-135.4)	Female	24	21.6	111.2	(71.2-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.1	nc	(nc-nc)	Male	15	16.1	93.0	(52.0-153.5)
<u>Colon / Rectum</u>					Female	17	9.1	186.2	(108.4-298.1)
Male	37	43.3	85.4	(60.1-117.7)	<u>Ovary</u>				
Female	39	46.5	83.9	(59.7-114.7)	Female	9	13.7	65.5	(29.9-124.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	10.1	188.5	(113.4-294.4)	Male	19	15.8	120.0	(72.2-187.5)
Female	8	3.3	243.3	(104.8-479.4)	Female	22	18.3	120.2	(75.3-182.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	137	107.0	128.0	(107.5-151.4)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	10.0	59.8	(21.8-130.2)
Male	17	20.3	83.6	(48.7-133.9)	Female	6	6.6	91.3	(33.4-198.8)
Female	11	13.3	82.4	(41.1-147.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.1	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.9	nc	(nc-nc)	Male	8	7.4	108.0	(46.5-212.8)
<u>Leukemia</u>					Female	12	21.4	56.0	(28.9-97.7)
Male	32	16.3	196.4	(134.3-277.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	12.6	175.0	(109.6-264.9)	Female	28	35.5	78.8	(52.4-114.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	13.0	161.8	(100.1-247.4)	Male	573	503.7	113.8	(104.6-123.5)
Female	9	5.3	169.7	(77.4-322.1)	Female	623	558.3	111.6	(103.0-120.7)
<u>Lung and Bronchus</u>									
Male	73	76.1	95.9	(75.2-120.6)					
Female	98	89.2	109.9	(89.2-133.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;